| Document |
Document Title |
|
WO/2009/026622A1 |
The present invention relates to a peptide for modulating an immune response, said peptide comprising an amino acid sequence corresponding to at least a portion of one of a Src homology 3 (SH3) domain, a Src homology 2 (SH2) domain, or a...
|
|
WO/2009/018500A1 |
The present invention discloses compositions which induce cross-activation of immune mediated and direct death signaling in targeted cells by exploiting the properties of a antibody/peptide-nucleic acid conjugate. The conjugate is able t...
|
|
WO/2009/006620A1 |
Provided are methods of producing, and compositions comprising, isolated alpha (2→8) or (2→9) oligosialic acid derivatives bearing a non-reducing end enriched for one or more de-N-acetyl residues and resistant to degradation by exone...
|
|
WO/2009/002516A1 |
The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infectio...
|
|
WO/2009/002274A1 |
There is presently provided a triblock peptide comprising a hydrophobic amino acid block, a histidine block and a cationic amino acid block. The triblock peptide may be used to form a nanoparticle for delivery of an agent into a cell.
|
|
WO/2008/147536A1 |
This invention relates to methods and compositions for enhancing proteasome activity in a cell. The methods and compositions for enhancing the activity of the proteasome in cells modulate the activity of Ubp6 (yeast) or Uspl4 (human), an...
|
|
WO/2008/143339A1 |
Disclosed is an amphipathic molecule having two or more zwitterionic functional groups in its hydrophilic moiety. Also disclosed is a molecular aggregate comprising the amphipathic molecule as a constituent lipid. The molecular aggregate...
|
|
WO/2008/140834A2 |
This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathog...
|
|
WO/2008/133886A1 |
Compositions are provided comprising a family of peptides having binding specificity for bone, and their use to produce coating compositions. The coating compositions are used to deliver a pharmaceutically active agent to bone, and are u...
|
|
WO/2008/133928A2 |
The present invention features methods of treating a patient having an epithelial lesion or disorder of impaired mucin function. The present invention further features methods of treating pain associated with epithelial lesions and disor...
|
|
WO/2008/128289A1 |
The invention herein includes a general method for reducing or eliminating a toxic effect of transgenic defensin expression in a host plant. The invention also includes a method of modifying a nucleic acid encoding a defensin, a nucleic ...
|
|
WO/2008/124139A1 |
Described herein are methods for the solubilization and proteolytic cleavage of fusion protein aggregates, including autocatalytic fusion proteins, at pressures greater than atmospheric pressure to yield soluble target polypeptides.
|
|
WO/2008/088548A2 |
Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin avß3 receptor-antagonist activity and substantially reduced integrin aIIbß3 and/or a5ß1 rec...
|
|
WO/2008/085191A1 |
The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses.
|
|
WO/2008/077194A1 |
The present invention relates to peptides that are useful as agonists of opioid receptors. In particular, the peptides have a sequence R1-Paa1-Z-Xaa1-Haa1-C1-C2-R2 wherein R1, R2, Paa1, Z, Xaa1, Haa1, C1 and C2 are defined in the specifi...
|
|
WO/2008/070021A2 |
A method for determining the effectiveness of a waste water tank deodorizer includes the steps of (i) providing a synthetic waste water media and a hydrogen sulfide generating microorganism; (ii) introducing in any order to the synthetic...
|
|
WO/2008/070047A2 |
The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially cancer stem cells. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimu...
|
|
WO/2008/059927A1 |
The object is to discover a collagen peptide composed of an oligopeptide having a higher ability of being transported into the blood compared to a conventional collagen peptide, and to provide a food or beverage having the collagen pepti...
|
|
WO/2008/034575A1 |
The iminosugar conjugates having the structural formula (I) with integer n≥0; R1, R2, being chosen from H, OH, NHAc, OGlycosyl, O(CH2)mCH3, or O(CF2)mCF3; R3, R4, R5, and R6 being chosen from H, OH, OGlycosyl, O(CH2)mCH3, or O(CF2)mCF3...
|
|
WO/2008/028251A1 |
The invention provides an isolated nucloprotein complex comprising a mammalian Ifi202 protein and foreign double stranded DNA, which complexes may be involved in intracellular recognition of, and cellular activation by, foreign double st...
|
|
WO/2008/024374A2 |
Disclosed herein are methods for regulation of fat and/or cholesterol uptake from the gastrointestinal tract and/or regulation of plasma fat and/or cholesterol levels comprising administering to a mammal in need thereof an effective amou...
|
|
WO/2008/014054A2 |
Human Bone Morphogenic Protein 7 (hBMP-7) variant peptide chains, nucleic acids encoding these peptide chains, and methods of making and using the foregoing are disclosed.
|
|
WO/2008/011335A2 |
Compositions are provided comprising a family of peptides having binding specificity for metal, and their use to produce coating compositions. The coating compositions are used to deliver a pharmaceutically active agent to metal, and are...
|
|
WO/2007/149490A1 |
This invention provides processes of purifying and recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof. Non-ionic dete...
|
|
WO/2007/113683A2 |
A method is provided for increasing glucose uptake of a cell, comprising modulating activity of Ariadne-1. Also provided is a method of treating hyperglycemia or a disorder related to hyperglycemia in a patient, comprising administering ...
|
|
WO/2007/108464A1 |
Disclosed is an anti-cytoplasmic sialidase monoclonal antibody which can recognize the conformation of a mammal-derived cytoplasmic sialidase and can neutralize the activity of a mammal-derived cytoplasmic sialidase. Also disclosed is a ...
|
|
WO/2007/106050A1 |
A competitive enzyme-linked immunosorbent assay (C-ELISA), using flavivirus member specific immunological agents was developed to detect antibody specific to members of the flaviviruses indicative of exposure to flavivirus. The test is b...
|
|
WO/2007/097903A2 |
Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9. SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO: 15; and provided is a pharmaceutical composition com...
|
|
WO/2007/095021A2 |
The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatmen...
|
|
WO/2007/086898A2 |
Disclosed are compositions and methods relating to the anthrax spore glycoproteins of Bacillus anthracis. Disclosed are the methods of using these compositions for vaccination against anthrax infection. Disclosed are BclA and BclB, compo...
|
|
WO/2007/064208A1 |
A protein hydrolysate having a degree of hydrolysis between 1 and 40% and containing between 1 and 70 wt.% of peptides having a molecular weight of less than 500 Da and less than 55 wt.% of peptides or proteins having a molecular weight ...
|
|
WO/2007/059597A2 |
|
|
WO/2007/051923A2 |
The invention relates to novel biodegradable materials based on modified polyomino acids and suitable, in particular, for vectoring active substance(s) (AS). Said invention also relates to novel pharmaceutical, cosmetic, dietary or plant...
|
|
WO/2007/045192A1 |
Disaccharide synthon I (benzyl-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→4)-2-ac
etamido-3-0-[1-(R)-carboxyethyl-2-deoxy-α-D-glucopyranoside
) and its use for synthesis of 2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→4)-N-acetylmura
...
|
|
WO/2007/043615A1 |
Disclosed is a method for ligation of proteins or constituent components thereof (e.g., amino acids, peptides) through an amide bond by using a peptide ester as a raw material. Also disclosed is a reagent which can be used suitably in th...
|
|
WO2006017913A9 |
The present invention provides a method for the screening of nucleic acid fragment expression libraries and selecting encoded peptides based upon their ability to modulate the activity of a target protein or nucleic acid and assume conse...
|
|
WO/2007/033424A1 |
The present invention is concerned with compositions capable of transfecting or otherwise delivering useful substances into cells and, more specifically, it is concerned with proteins and peptides capable of translocation across cell mem...
|
|
WO/2007/034809A1 |
It is intended to provide a host cell which can be proliferated in a serum-free medium, synthesize and secret a desired protein in a large amount and produce a glycoprotein having a sugar chain structure. Namely, an established cell line...
|
|
WO/2007/030889A1 |
The present invention relates to a marker for the development of pre-eclampsia. In particular the invention provides a marker for the development of pre-eclampsia, which marker consists of a polypeptide of approximately 26.6 Kd as determ...
|
|
WO/2007/032634A1 |
The present invention relates to a ligand of AxI receptor tyrosine kinase used to induce the differentiation from precursor natural killer cell to mature natural killer-cell. In addition, it relates to a process for producing mature natu...
|
|
WO/2007/030890A1 |
The present invention relates to amniotic fluid specific polypeptide and a method for detecting rupture of the amniotic membranes. In particular the invention provides a marker for prolonged rupture of the membranes (PROM), which marker ...
|
|
WO/2007/021016A1 |
A method for photoregulating the formation of a complex between a protein of interest and a peptide capable of recognizing the protein, wherein a structural change in the peptide that is used for the recognition of the protein is photore...
|
|
WO/2007/021253A1 |
The inventors have discovered that an ATPase-deficient dominantnegative mutant NS3 protein of hepatitis C virus inhibits activity of the wild-type NS3 protein and inhibits replication of hepatitis C virus (HCV). The solved crystal stru...
|
|
WO/2006/138721A1 |
Antibodies and antibody fragments that bind to the receptor GFRalpha3 and inhibit formation of a Neublastin-GFRalpha3-Ret ternary complex are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit...
|
|
WO/2006/135371A1 |
A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent ahs been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is clea...
|
|
WO/2006/133196A1 |
The present invention relates to autoantigenic vaccine peptides comprising a universal helper T cell epitope portion linked to a B cell epitope portion from the N-terminus of cholesteryl ester transfer protein (CETP). The vaccine peptide...
|
|
WO/2006/128027A1 |
A method is disclosed for inhibiting angiogenic activity by interacting anginex with the peptide galectin-1. Also disclosed is a method for constructing an artificial gene encoding the biologically exogenous peptide anginex and producing...
|
|
WO/2006/114528A1 |
The invention relates to the use of monomers of active a-amino acids for the preparation of hydrophobic polypeptides in the form of precipitates, whereby the polypeptides result from the polymerisation of the aforementioned monomers of a...
|
|
WO/2006/111060A1 |
The present invention provides a method for isolating and purifying immuno-modulating polypeptide from cow placenta, which is characterized by using the steps of anion-exchange chromatography, gel exclusion chromatography and reverse-pha...
|
|
WO/2006/098326A1 |
Disclosed is a complex for a biocompatible material which has no risk of causing infection with a pathogen or any adverse side effect (e.g., rejection). A complex for a biocompatible material, comprising a polypeptide comprising peptide ...
|
